Takahito Negishi

Fukuoka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 68 publications

JAVEMACS: a real-world study of avelumab maintenance therapy for advanced urothelial carcinoma in Japan.

JAVEMACS: a real-world study of avelumab maintenance therapy for advanced urothelial carcinoma in Japan.

Journal: ESMO real world data and digital oncology

Published: August 08, 2026

Prognostic impact of regional lymph node metastasis at castration-resistant prostate cancer diagnosis on survival after radium-223 treatment.

Prognostic impact of regional lymph node metastasis at castration-resistant prostate cancer diagnosis on survival after radium-223 treatment.

Journal: Japanese journal of clinical oncology

Published: May 22, 2026

Differences in Unmet Needs Between Older and Younger Patients With Advanced Renal Cell Carcinoma.

Differences in Unmet Needs Between Older and Younger Patients With Advanced Renal Cell Carcinoma.

Journal: Anticancer research

Published: May 16, 2026

Ureteral Orifice Stricture After Transurethral Resection of Bladder Tumors Involving the Ureteral Orifice or Adjacent Area: Clinical Course and Outcomes.

Ureteral Orifice Stricture After Transurethral Resection of Bladder Tumors Involving the Ureteral Orifice or Adjacent Area: Clinical Course and Outcomes.

Journal: In vivo (Athens, Greece)

Published: April 08, 2026

Real-world Implementation of Adjuvant Pembrolizumab for High-risk Clear-cell Renal Cell Carcinoma After Surgery.

Real-world Implementation of Adjuvant Pembrolizumab for High-risk Clear-cell Renal Cell Carcinoma After Surgery.

Journal: In vivo (Athens, Greece)

Published: April 01, 2026

Early Progressive Disease During Nivolumab Plus Ipilimumab Therapy Predicts Poor Survival in Japanese Patients with Advanced Renal Cell Carcinoma: A Single-Center 12-Week Landmark Study.

Early Progressive Disease During Nivolumab Plus Ipilimumab Therapy Predicts Poor Survival in Japanese Patients with Advanced Renal Cell Carcinoma: A Single-Center 12-Week Landmark Study.

Journal: Research and reports in urology

Published: March 27, 2026

Early Progressive Disease Predicts Poor Outcomes of Second-line VEGFR Tyrosine Kinase Inhibitor Therapy After First-line Nivolumab Plus Ipilimumab in Advanced Renal Cell Carcinoma.

Early Progressive Disease Predicts Poor Outcomes of Second-line VEGFR Tyrosine Kinase Inhibitor Therapy After First-line Nivolumab Plus Ipilimumab in Advanced Renal Cell Carcinoma.

Journal: Anticancer research

Published: March 04, 2026

Older Age and Outcomes of Intravesical Bacillus Calmette-Guérin for Non-muscle-invasive Bladder Cancer.

Older Age and Outcomes of Intravesical Bacillus Calmette-Guérin for Non-muscle-invasive Bladder Cancer.

Journal: In vivo (Athens, Greece)

Published: February 07, 2026

Real-world Delivery and Outcomes of Intravesical BCG for Non-muscle-invasive Bladder Cancer.

Real-world Delivery and Outcomes of Intravesical BCG for Non-muscle-invasive Bladder Cancer.

Journal: Anticancer research

Published: February 05, 2026

Real-world Treatment Selection and Shared Decision-making in De Novo Metastatic Castration-sensitive Prostate Cancer in Japan.

Real-world Treatment Selection and Shared Decision-making in De Novo Metastatic Castration-sensitive Prostate Cancer in Japan.

Journal: Cancer diagnosis & prognosis

Published: November 26, 2025

Perioperative Chemotherapy in Bladder and Upper Tract Urothelial Carcinoma: Outcomes by Nodal Status and Lymphovascular Invasion.

Perioperative Chemotherapy in Bladder and Upper Tract Urothelial Carcinoma: Outcomes by Nodal Status and Lymphovascular Invasion.

Journal: Cancers

Published: November 12, 2025

Avelumab maintenance therapy for advanced urothelial carcinoma: subgroup analyses by characteristics of first-line platinum-based chemotherapy from a real-world chart review study in Japan (JAVEMACS).

Avelumab maintenance therapy for advanced urothelial carcinoma: subgroup analyses by characteristics of first-line platinum-based chemotherapy from a real-world chart review study in Japan (JAVEMACS).

Journal: BMC cancer

Published: September 23, 2025

Showing 1-12 of 68

Last Updated: 09/26/2026